14 September 2017 - - The global pulmonary drug delivery devices/systems market is expected to reach USD 55.1bn by 2025, according to a new report by US based market research and consulting company Grand View Research, Inc.

An increasing prevalence of chronic respiratory diseases is expected to boost the adoption of Pulmonary Drug Delivery Systems.

As per WHO, 235 m people suffer from asthma globally. Majority of the asthma related deaths occur in middle- to low-income countries due to lack of treatment options.

This shows the potential demand for pulmonary drug delivery systems in the coming years.

Technological advancements in the field of drug delivery are expected to positively impact the pulmonary drug delivery devices market.

These advancements include incorporation of agglomerated vesicle technology, MDI electronic dose counter, particle engineering, and supercritical fluid technology. Rising demand for new products, changing lifestyle, ease of use, and better facilities are factors expected to provide lucrative opportunities.

Furthermore, rise in number of public and private organizations is another major factor propelling the growth of pulmonary drug delivery devices market. For instance, organizations such as the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI) are engaged in providing information in clinical and basic research on allergy, asthma, and clinical immunology.

Such initiatives are in turn expected to increase the market demand for respiratory drug delivery devices in developing regions, thereby boosting overall market growth.